EDITORIAL SECTION
-
STRATEGY
Smarter Pharma
Quality management systems QMS are the backbone of pharmaceutical manufacturing ensuring safe products
-
RESEARCH DEVELOPMENT
Cytiva Laboratory capsule filters
Our singleuse selfcontained filtration solution
-
CLINICAL TRIALS
Why Clinical Trials Need Digital Endpoints
According Citeline the average success rate for bringing a Phase candidate to market has dropped to an alltime low of just
-
MANUFACTURING
Ensuring Quality and Compliance in Biopharma
Ensuring quality and regulatory compliance in the biopharmaceutical industry is critical to safeguarding product safety and efficacy
-
Information Technology
The Cost of Bad Data
Modern pharmaceutical research generates an unprecedented volume of information Data from genomic sequencing
-
Biopharma
Reimagining Global Biomanufacturing Capacity with Continuous and Modular Systems
Biotechnology is fueling the ongoing expansion of the global market for a broad array of goods
-
EXPERT Talk
Compliance to Competitive Advantage in Pharma Supply
Compliance gets you through an audit Resilience gets medicines to patients on the day something unexpected happens The DSCSAs enhanced requirements took effect November but real interoperability required three more rounds of accommodation phased implementation with the smalldispenser
Advisory Board
KNOWLEDGE BANK
-
Articles
What Is Pharmaceutical Logistics? Top 7 Pharmaceutical Logistics Challenges and Solutions
Pharmaceutical logistics is an important part of the health systems ecosystem and ensures that drugs and medical products that are conscious of patients safely effectively and on time In the core pharmaceutical logistics management includes planning implementation and control of movement and storage of pharmaceutical goods in the supply chain Given the sensitive nature of these products it is nece...
Market Access Strategies for Pharma Products in Europe: A Comprehensive Guide
The European pharmaceutical market is dynamic and diverse presenting both opportunities and challenges for companies seeking market access This guide delves into effective strategies for navigating the complexities of market access in Europe focusing on key aspects such as reimbursement pricing and overcoming market entry challenges
Why Leading Pharma Professionals Rely on the Pharma Focus Europe E-Newsletter
The network of the pharmaceutical and life sciences in Europe is undergoing a radical transformation There are changes in the regulatory environments a rise in the pace of innovation a shift in leadership and a change in the distribution production and development of therapies by the use of digital technologies In this environment no longer will access to timely credible and context rich informati...
Adaptive Trial Designs: Enhancing Speed and Decision-Making in Clinical Development
For decades the traditional clinical trial has followed a rigid script A protocol is written patients are enrolled the study runs to completion and only at the very end does the sponsor learn whether the investment paid off The model has served the industry well in terms of scientific rigour
Designing Early-stage Formulation Strategies for Anti-microbial Peptides (Amps): A Major Prerequisite for Combating Anti-microbial Resistance
At present the world is witnessing an exponential increase in antimicrobial resistance AMR making it important for us to search alternatives to antibiotics in order to combat multidrug resistant MDR bacterial infections According to a study drugresistant infections were responsible for million deaths in globally The number of predicted deaths
Radical Optionality to Leadership Reinvention: Dual Framework for Biotech-CDMO Transformation
Biotech and CDMOs stand at a pivotal crossroads On one side scientific complexity is acceleratingnew modalities such as antibodydrug conjugates mRNA oligonucleotides and cell and gene therapies demand faster more adaptive development models On the other side systemic pressures are tighteningthe biotech funding squeeze the Biosecure Act and fractured global supply chains are forcing organisations t...
-
Techno Trends
Alume Biosciences Secures FDA Breakthrough Therapy Designation for Bevonescein
Alume Biosciences has received Breakthrough Therapy Designation BTD from the US Food and Drug Administration FDA for bevonescein an investigational fluorescent drug being developed to support realtime nerve visualisation during head and neck surgery in adults Bevonescein is an intravenous fluorescent peptidedye conjugate that binds to nerve tissue
-
Projects
SK pharmteco Plans More Than US$200 Million Investment in Small Molecule and Peptide Manufacturing
SK pharmteco is planning a fiveyear investment of more than US million to expand and modernise its pharmaceutical development and manufacturing operations in the United States The programme will strengthen capabilities for small molecules and peptides while supporting a more
-
Research Insights
A drug repurposing screen reveals dopamine signaling as a candidate therapeutic pathway for PIGA-CDG
PIGACDG is a congenital disorder of glycosylation caused by pathogenic partial lossoffunction variants in the PIGA gene PIGA encodes an enzyme responsible for the catalytic transfer of Nacetylglucosamine
-
whitepaper
Post-Translational Modifications in Drug Discovery: From Molecular Regulation to Clinical Impact
For decades the central dogma of molecular biology has anchored our understanding of cellular function DNA to RNA to protein But this linear view is incomplete A growing body of evidence shows that much of biologys
TOP ARTICLES
-
1
Market Access Strategies for Pharma Products in Europe: A Comprehensive Guide
Kate Williamson
This comprehensive guide provides pharmaceutical companies with strategic insights for navigating the diverse European market. Focusing on reimbursement, pricing, and market entry challenges, it empha...
-
2
-
3
Adaptive Trial Designs: Enhancing Speed and Decision-Making in Clinical Development
Lakshmi
Clinical development remains the most expensive and uncertain stage of bringing a medicine to market, with fixed, linear trial designs often committing billions to hypotheses that could have been test...
-
4
Designing Early-stage Formulation Strategies for Anti-microbial Peptides (Amps): A Major Prerequisite for Combating Anti-microbial Resistance
Sintu Kumar Samanta
Ananya Anurag Anand
Biological formulation of drugs is critical to ensure their effective delivery within the patient’s body. It involves the determination of appropriate substances that can be combined with active...
-
5
Radical Optionality to Leadership Reinvention: Dual Framework for Biotech-CDMO Transformation
Dr. Kishore Hotha
This paper presents a dual framework uniting radical optionality and reinvented leadership to transform biotech–CDMO performance. By embedding flexibility in systems, capability-based leadership...
press releases Read more...
Fortrea and Omico Collaboration to Advance Biomarker-led Oncology Drug Development
Fortrea a leading global contract research organization CRO and Omico Australias leading precision oncology screening and trial matching organization today announced a collaboration to accelerate precision oncology research by helping connect cancer patients to biomarkermatched clinical trials By co...
ZEGFROVY® (sunvozertinib) now available in the US for patients with previously treated non-small cell lung cancer with EGFR exon 20 insertion mutations
AstraZeneca today announced the US availability of ZEGFROVY sunvozertinib for the treatment of adults with locally advanced or metastatic nonsmall cell lung cancer NSCLC whose tumors have epidermal growth factor receptor EGFR exon insertion mutations as detected by an FDAapproved test
Cardiff Oncology Receives FDA Orphan Drug Designation for Onvansertib in Chronic Myelomonocytic Leukemia
Cardiff Oncology Inc a clinicalstage biotechnology company leveraging PLK inhibition to develop novel cancer therapies today announced that the US Food and Drug Administration FDA has granted Orphan Drug Designation to onvansertib for the treatment of patients with chronic myelomonocytic leukemia
Geneos Therapeutics Initiates IMPACT31 Phase 2 Randomized Clinical Trial Evaluating Neoantigen-Targeted Personalized DNA Immunotherapy for Cancer
Geneos Therapeutics a clinical stage biotherapeutics company focused on the development of neoantigenbased personalized immunotherapy for cancer PIC today announced the initiation of its Phase randomized clinical trial NCT in patients with highrisk hepatocellular carcinoma HCC liver cancer
Events Read more...
26 - 28
Oct 2026ACHEMA Middle East 2026
RICEC, Riyadh, KSA, Saudi Arab...
26 - 28
Oct 2026World Orphan Drug Congress
RAI, Amsterdam, Netherlands
27 - 28
Oct 2026Pharma Manufacturing & Automation Convention 2026
Novotel Hyderabad Airport, Ind...
28 - 30
Oct 2026BIOPLUS-INTERPHEX KOREA 2026
COEX, Seoul
02 - 04
Nov 2026Pharma Forum EMEA 2026
Dom Pedro Lisboa Hotel, Lisbon...
02 - 04
Nov 2026Cancer R&D 2026
Houston, TX, USA
03 - 05
Nov 202610th Dermatology Drug Development
Boston, Massachusetts at The C...
03 - 04
Nov 2026PDA Aseptic Processing of Biopharma Conference
Sheraton Grand Incheon Hotel,...
LATEST NEWS Read more...
Georgiamune and Menarini Group Enter Exclusive Global License and Collaboration Agreement for GIM-621, a First-in-Class Oral Immuno-Oncology Agent
The Menarini Group a leading international pharmaceutical and diagnostics company and Stemline Therapeutics Inc Stemline a whollyowned subsidiary of the Menarini Group focused on bringing transformational oncology treatments to cancer patients along with Georgiamune Inc a clinicalstage biotechnology...
LGM Pharma Acquires Sannova Analytical, Expanding cGMP Analytical and GLP Bioanalytical Services
LGM Pharma a leading provider of tailored API sourcing contract analytical testing and drug development services today announced it has acquired Sannova Analytical a contract research laboratory headquartered in Somerset NJ The acquisition expands LGM Pharmas analytical testing services business by...
AI Proteins Announces Research Collaboration and License Agreement With Astellas Pharma to Discover and Develop Novel Miniprotein-Based Therapeutics Valued at Over $400 Million
AI Proteins Inc a biotechnology company that utilizes computational de novo protein design to create therapeutic miniproteins today announced it has entered into a Research Collaboration and License Agreement with Astellas Innovation Management LLC an affiliate of Astellas Pharma Inc TSE to discove...
Okomera Announces Trade Agreement with Servier to Use Tumor Miniaturization Technology in Cancer Research
Okomera a TechBio company that personalizes cancer management with its technology combining minivatars tumor microfluidics and AI imaging today announced the signing of a commercial agreement with Servier an independent international pharmaceutical group
ScionxBio Announces Collaboration to Develop Long-Acting xRNA Therapeutics
ScionxBio a privately held preclinicalstage biotechnology company pioneering nextgeneration mRNA therapeutics distinguished by their extended durability profile today announced that it has entered into a worldwide strategic collaboration and licensing agreement with Sanofi
Takara Bio USA Partners with SPT Labtech to Deliver Automation-Ready NGS Library Preparation Technologies
Takara Bio USA Inc a wholly owned subsidiary of Takara Bio Inc and SPT Labtech today announced their partnership to deliver validated automated library preparation workflows that combine Takara Bio nextgeneration sequencing NGS library preparation chemistries with SPT Labtechs firefly liquid handlin...





